Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

Irazú Contreras-Yáñez, Virginia Pascual-Ramos, Irazú Contreras-Yáñez, Virginia Pascual-Ramos

Abstract

Introduction: Benefits of disease-modifying anti-rheumatic drugs (DMARD) in early rheumatoid arthritis patients (ERAP) will be achieved if patients follow prescribed treatment. Objective was to investigate whether timing of first non-persistence period and/or duration of persistence during the first 4 years of follow-up predicted disease outcomes at the 5(th) year in a cohort of ERAP, initiated in 2004.

Patients and methods: Up to February 2015, charts of 107 ERAP with at least 5 years of follow-up and prospective 6-month assessments of disease activity, disability and persistence were reviewed. Non-persistence was defined as omission of DMARD and/or corticosteroids for at least 7 consecutive days; regarding methotrexate, one weekly missing dose was considered non-persistence. Persistence was recorded through an interview (up to 2008) and thereafter through a questionnaire; persistence duration was recorded in months of continuous medicationtaking. At the 5(th) year, disease activity was defined according to Disease Activity Score (DAS)28, and disability according to Health Assessment Questionnaire (HAQ). Descriptive statistics and linear and Cox regression analyses were used.

Results: At study entry, patients were more frequently middle-aged (39.1 ± 13.3 years) and female (88.8%), as well as more likely to have high disease activity and disability. Over the first 4 years of follow-up, 54.2% of the patients had indications for oral corticosteroids and all traditional DMARDs. Almost 70% had at least one period of non-persistence, and their follow-up (median, 25th-75th interquartile range) to first non-persistence period was 13 months (1-31). Persistence duration during the first 4 years predicted subsequent DAS28 (in addition to gender and baseline DAS28) and HAQ (in addition to age). During the 5(th) year, 68 patients (56 women) achieved sustained remission (DAS28 < 2.6). In female population (n = 95), baseline DAS28 (odds ratio [OR], 0.65; 95 % confidence interval [CI], 0.50-0.83; p = 0.001) and persistence duration (OR, 1.04; 95 % CI, 1-1.08; p = 0.05) were predictors. Also, 84 patients achieved sustained function (HAQ <0.21), and baseline DAS28 and age were the only predictors. Timing of first non-persistence period did not impact outcomes.

Conclusions: Persistence duration with DMARDs within the first 4 years of RA predicted subsequent favorable outcomes in ERAP; additional predictors were younger age, male gender and lower disease activity at diagnosis.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic curve for cutoff for persistence duration to predict sustained remission. Curve plots the relationship between sensitivity and specificity for the persistence duration cutoff to predict SR at the fifth year of follow-up

References

    1. Cush JJ. Early rheumatoid arthritis – is there a window of opportunity? J Rheumatol Suppl. 2007;80:1–7.
    1. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61:4–12. doi: 10.1002/art.24367.
    1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9. doi: 10.1016/S0140-6736(04)16676-2.
    1. Van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337–51. doi: 10.1586/eci.12.23.
    1. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: Author; 2003. . Accessed 1 July 2015.
    1. De Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.
    1. Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334:248–54. doi: 10.1097/MAJ.0b013e318068dde8.
    1. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol. 1981;8:931–6.
    1. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:743–6. doi: 10.1007/s00296-006-0299-9.
    1. García-González A, Richardson M, García Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–9. doi: 10.1007/s10067-007-0816-6.
    1. Lorish CD, Richards B, Brown S. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res. 1990;3:78–84.
    1. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol. 1999;26:2114–22.
    1. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance with drug therapy in rheumatoid arthritis: a longitudinal European study. Joint Bone Spine. 2000;67:178–82.
    1. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45:S66–76. doi: 10.1097/MLR.0b013e318041384c.
    1. Pascual Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet Medication persistence over two years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and disability. Arthritis Res Ther. 2009;11:R26. doi: 10.1186/ar2620.
    1. Contreras-Yáñez I, Ponce de León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease modifying antirheumatic drugs. Am J Med Sci. 2010;340:282–90. doi: 10.1097/MAJ.0b013e3181e8bcb0.
    1. Contreras-Yáñez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician-, and laboratory-reported outcomes in recent onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748–51.
    1. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5:119–29. doi: 10.1002/art.1790050303.
    1. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8. doi: 10.1002/art.1780380107.
    1. de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5:313–26. doi: 10.2217/ijr.10.15.
    1. Pasma A, van’t Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43:18–28. doi: 10.1016/j.semarthrit.2012.12.001.
    1. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29:260–75. doi: 10.1097/NOR.0b013e3181e5c2c9.
    1. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33:901–13. doi: 10.1016/j.clinthera.2011.06.001.
    1. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55. doi: 10.1186/1472-6963-7-55.
    1. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med. 1996;124:699–707. doi: 10.7326/0003-4819-124-8-199604150-00001.
    1. Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G, et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol. 2002;20:351–8.
    1. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906–14. doi: 10.1093/rheumatology/keh199.
    1. Lard LR, Visser H, Speyer I, Vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446–51. doi: 10.1016/S0002-9343(01)00872-5.
    1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7. doi: 10.1111/j.1524-4733.2007.00213.x.
    1. Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, et al. Efficacy and safety of golimumab as add-on therapy to disease modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014;73:477–86.
    1. ten Klooster PM, Vonkeman HE, Oude Voshaar MAH, Siemons L, van Riel PLCM, van de Laar MAFJ. Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. Rheumatology (Oxford) 2015;54:1080–6. doi: 10.1093/rheumatology/keu449.
    1. Ma MH, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PD, et al. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol. 2012;39:470–5. doi: 10.3899/jrheum.110169.
    1. Castrejón I, Dougados M, Combe B, Guillemin F, Fautrel B, Pincus T. Analysis of potential predictors for remission in early rheumatoid arthritis according to ACR/EULAR Boolean, DAS28 and RAPID3RJ1 criteria: results from the ESPOIR cohort [OP0133] Ann Rheum Dis. 2013;72:A96–7. doi: 10.1136/annrheumdis-2013-eular.338.
    1. Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, et al. Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inceptions cohorts. Semin Arthritis Rheum. 2014;44:131–44. doi: 10.1016/j.semarthrit.2014.05.003.
    1. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) 2000;39:603–11. doi: 10.1093/rheumatology/39.6.603.
    1. Wiles N, Dunn G, Barrett E, Silman A, Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. J Clin Epidemiol. 2000;53:988–96. doi: 10.1016/S0895-4356(00)00189-X.
    1. Forslind K, Hafström I, Ahlmén M, Svensson B, BARFOT Study Group Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66:46–52. doi: 10.1136/ard.2006.056937.
    1. Schipper LG, Fransen J, den Broeder AA, Van Riel PLCM. Time to achieve remission determines to be in remission. Arthritis Res Ther. 2010;12:R97. doi: 10.1186/ar3027.
    1. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol. 2008;22:621–41. doi: 10.1016/j.berh.2008.04.003.
    1. Krishnan E, Sokka T, Häkkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50:953–60. doi: 10.1002/art.20048.
    1. Sokka T, Kautiainen H, Hannonen P, Pincus T. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum. 2006;54:3113–8. doi: 10.1002/art.22130.
    1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes and obesity-related health risks factors. JAMA. 2003;289:76–9. doi: 10.1001/jama.289.1.76.
    1. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etarnecept and infliximab in rheumatoid arthritis: results from a six-year observational study in Southern Sweden. Arthritis Res Ther. 2006;8:R174. doi: 10.1186/ar2084.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir